Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 10/20 | 0.57 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.57 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.57 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.57 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.57 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.57 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | PGK1 | P00558 | 1/20 | 0.48 |
| ▸ | PGK2 | P07205 | 1/20 | 0.48 |
| ▸ | PGD | P52209 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4572575 | 1.00 | LPAR1 (0.57) | LPAR1LPAR5LPAR4LPAR2LPAR3 | |
| SCHEMBL19485403 | 0.83 | LPAR1 (0.42) | LPAR1LPAR5LPAR4LPAR2LPAR3 | |
| SCHEMBL304203 | 0.82 | TDP1 (0.54) | — | |
| SCHEMBL1286423 | 0.82 | PGK1 (0.58) | LPAR1LPAR5LPAR4LPAR2LPAR3 | |
| SCHEMBL4572553 | 0.82 | P2RY10 (0.43) | LPAR1LPAR5LPAR4LPAR2LPAR3 | |
| SCHEMBL9175087 | 0.82 | TSHR (0.52) | LPAR1LPAR5LPAR4LPAR2LPAR3 | |
| SCHEMBL15385433 | 0.82 | P2RY10 (0.46) | LPAR1LPAR5LPAR4LPAR2LPAR3 | |
| SCHEMBL19960604 | 0.81 | LPAR1 (0.67) | LPAR1LPAR5LPAR4LPAR2LPAR3 | |
| SCHEMBL14823175 | 0.79 | P2RY10 (0.47) | LPAR1LPAR5LPAR4LPAR2LPAR3 | |
| SCHEMBL10623420 | 0.78 | LPAR1 (0.47) | LPAR1LPAR5LPAR4LPAR2LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343934-B2 | Diverse lead compound autotaxin inhibitors | UNIVERSITY OF MEMPHIS (US) | 2013-01-01 | — | — | US | disclosed |
| US-8268891-B1 | Autotaxin inhibitors | UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120100592-A1 | PIPEMIDIC ACID DERIVATIVE AUTOTAXIN INHIBITORS | THE UNIVERSITY OF MEMPHIS | 2012-04-26 | — | — | US | disclosed |
| US-8022239-B2 | Mechanism-based inactivators of autotaxin | THE UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110160148-A1 | Novel Diverse Lead Compound Autotaxin Inhibitors | THE UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION (US) | 2011-06-30 | — | — | US | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20100136650-A1 | MECHANISM-BASED INACTIVATORS OF AUTOTAXIN | THE UNIVERSITY OF MEMPHIS | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160148-A1 | Novel Diverse Lead Compound Autotaxin Inhibitors | ENPP2, ABHD16A, PLAAT2 | LPAR1 111/4885LPAR5 155/4885LPAR4 175/4885 |
| US-20120100592-A1 | PIPEMIDIC ACID DERIVATIVE AUTOTAXIN INHIBITORS | ENPP2, PLA2G6, PLA2G10 | LPAR1 53/4885LPAR5 60/4885LPAR4 123/4885 |
| US-20100136650-A1 | MECHANISM-BASED INACTIVATORS OF AUTOTAXIN | ENPP2, PLA2G12A, PLA2G10 | LPAR1 93/4885LPAR5 105/4885LPAR4 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.